心脏移植后免疫抑制手段中的一种潜在药物：贝拉西普。
A potential drug in the armamentarium of post-cardiac transplantation immunosuppression: belatacept.
作者信息
Sharma Dhruva, Sharma Neha
机构信息
Department of Cardiothoracic & Vascular Surgery, SMS Medical College & Attached Group of Hospitals, Jaipur, India.
Department of Pharmacology, SMS Medical College, Jaipur, India.
出版信息
Indian J Thorac Cardiovasc Surg. 2020 Nov;36(6):625-628. doi: 10.1007/s12055-020-00991-4. Epub 2020 Jul 10.
Abstract
Undeterred by all the advancement in the field of cardiac transplantation, heart transplant rejection remained its mammoth quandary. Management of heart transplant recipients has drastically improved with current regimens of immunosuppressive drugs. The adverse effects of calcineurin inhibitors are lacking with the use of belatacept, which is a costimulation inhibitor that interferes with the interaction between CD28 on T cells and the B7 ligands on antigen-presenting cells. It was originally approved for use in renal transplant recipients but it has shown promising results in heart transplant recipients.
摘要
尽管心脏移植领域取得了诸多进展，但心脏移植排斥反应仍然是一个巨大的难题。目前的免疫抑制药物方案已使心脏移植受者的管理有了显著改善。使用贝拉西普（一种共刺激抑制剂，可干扰T细胞上的CD28与抗原呈递细胞上的B7配体之间的相互作用）时，钙调神经磷酸酶抑制剂的不良反应并不存在。它最初被批准用于肾移植受者，但在心脏移植受者中也显示出了令人鼓舞的结果。
相似文献
1
A potential drug in the armamentarium of post-cardiac transplantation immunosuppression: belatacept.心脏移植后免疫抑制手段中的一种潜在药物：贝拉西普。
Indian J Thorac Cardiovasc Surg. 2020 Nov;36(6):625-628. doi: 10.1007/s12055-020-00991-4. Epub 2020 Jul 10.
2
Belatacept for maintenance immunosuppression in cardiothoracic transplantation: The potential frontier.贝那普利特在心胸器官移植中的维持免疫抑制治疗：潜在的前沿。
Clin Transplant. 2018 Oct;32(10):e13363. doi: 10.1111/ctr.13363. Epub 2018 Sep 10.
3
Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors.贝伐珠单抗对肾移植受者和健康供者病毒特异性记忆 T 细胞与新产生的同种异体 T 细胞反应的差异影响。
Transpl Immunol. 2020 Aug;61:101291. doi: 10.1016/j.trim.2020.101291. Epub 2020 Apr 21.
4
Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.贝利尤单抗：肾移植后维持免疫抑制的新型生物制剂。
Pharmacotherapy. 2011 Apr;31(4):394-407. doi: 10.1592/phco.31.4.394.
5
Belatacept: from rational design to clinical application.贝他西普：从合理设计到临床应用。
Transpl Int. 2012 Feb;25(2):139-50. doi: 10.1111/j.1432-2277.2011.01386.x. Epub 2011 Dec 7.
6
Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors.钙调磷酸酶抑制剂治疗失败的肺移植受者中维持贝利尤单抗免疫抑制治疗。
Transplantation. 2018 Jan;102(1):171-177. doi: 10.1097/TP.0000000000001873.
7
Costimulation Blockade in Kidney Transplant Recipients.肾移植受者的共刺激阻断。
Drugs. 2020 Jan;80(1):33-46. doi: 10.1007/s40265-019-01226-6.
8
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.在肾移植受者中从钙调磷酸酶抑制剂转换至贝利尤单抗后的 3 年安全性和疗效结局：一项 2 期随机试验的结果。
Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.
9
De Novo Belatacept in a Kidney-After-Heart Transplant Recipient.心脏移植术后肾移植受者中使用的新型贝拉西普
Transplant Direct. 2019 Dec 24;6(1):e515. doi: 10.1097/TXD.0000000000000967. eCollection 2020 Jan.
10
No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients.肝移植受者使用贝利尤单抗治疗不会增强色氨酸 2,3-双加氧酶（IDO）活性。
Clin Exp Immunol. 2018 May;192(2):233-241. doi: 10.1111/cei.13093. Epub 2018 Feb 2.
引用本文的文献
1
Insight into Noninvasive Radiological Modalities to Detect Heart Transplant Rejection.洞察用于检测心脏移植排斥反应的非侵入性放射学方法。
Indian J Radiol Imaging. 2022 Jan 11;31(4):946-955. doi: 10.1055/s-0041-1741098. eCollection 2021 Oct.
本文引用的文献
1
De Novo Belatacept in a Kidney-After-Heart Transplant Recipient.心脏移植术后肾移植受者中使用的新型贝拉西普
Transplant Direct. 2019 Dec 24;6(1):e515. doi: 10.1097/TXD.0000000000000967. eCollection 2020 Jan.
2
Belatacept for maintenance immunosuppression in cardiothoracic transplantation: The potential frontier.贝那普利特在心胸器官移植中的维持免疫抑制治疗：潜在的前沿。
Clin Transplant. 2018 Oct;32(10):e13363. doi: 10.1111/ctr.13363. Epub 2018 Sep 10.
3
Belatacept rescue for delayed kidney allograft function in a patient with previous combined heart-liver transplant.在一名曾接受心脏-肝脏联合移植的患者中，使用贝拉西普挽救延迟的肾移植功能。
Am J Transplant. 2018 Oct;18(10):2613-2614. doi: 10.1111/ajt.15003. Epub 2018 Aug 3.
4
Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors.钙调磷酸酶抑制剂治疗失败的肺移植受者中维持贝利尤单抗免疫抑制治疗。
Transplantation. 2018 Jan;102(1):171-177. doi: 10.1097/TP.0000000000001873.
5
Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.接受贝拉西普与环孢素治疗的扩大标准供肾受者的长期预后：III期随机研究BENEFIT-EXT的最终结果
Am J Transplant. 2016 Nov;16(11):3192-3201. doi: 10.1111/ajt.13830. Epub 2016 Jun 9.
6
Belatacept for renal rescue in lung transplant patients.贝拉西普用于肺移植患者的肾脏挽救治疗。
Transpl Int. 2016 Apr;29(4):453-63. doi: 10.1111/tri.12731. Epub 2016 Feb 8.
7
Belatacept for Maintenance Immunosuppression in Lung Transplantation.贝拉西普用于肺移植维持免疫抑制治疗
J Investig Med High Impact Case Rep. 2014 Sep 22;2(3):2324709614546866. doi: 10.1177/2324709614546866. eCollection 2014 Jul-Sep.
8
Belatacept maintenance in a heart transplant recipient.
Transplantation. 2014 Oct 15;98(7):e74-5. doi: 10.1097/TP.0000000000000404.
9
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.初治肝移植受者中基于贝拉西普的免疫抑制：一项II期随机研究的1年经验
Am J Transplant. 2014 Aug;14(8):1817-27. doi: 10.1111/ajt.12810.
10
Belatacept: is there BENEFIT for liver transplantation too?
Am J Transplant. 2014 Aug;14(8):1717-8. doi: 10.1111/ajt.12806.
Zotero 插件